Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Blood

Volumn 129, Issue 25, 2017, Pages 3322-3331

  Gardner, Rebecca A ^a,b   Finney, Olivia ^a   Annesley, Colleen ^a,b   Brakke, Hannah ^a   Summers, Corinne ^a,b   Leger, Kasey ^a   Bleakley, Marie ^b,c   Brown, Christopher ^a   Mgebroff, Stephanie ^a   Kelly Spratt, Karen S ^a   Hoglund, Virginia ^a   Lindgren, Catherine ^a   Oron, Assaf P ^a   Li, Daniel ^d   Riddell, Stanley R ^c,e   Park, Julie R ^a,b   Jensen, Michael C ^a,b,c  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d Juno Therapeutics   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLINATUMOMAB; CD14 ANTIGEN; CD19 ANTIGEN; CD27 ANTIGEN; CD3 ANTIGEN; CD39 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHIMERIC ANTIGEN RECEPTOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FAS ANTIGEN; FLUDARABINE; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; PROGRAMMED DEATH 1 RECEPTOR; TOCILIZUMAB; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; APHERESIS; ARTICLE; B CELL LEUKEMIA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CD4 CD8 RATIO; CELL CULTURE; CELL DEDIFFERENTIATION; CHILD; CLINICAL ARTICLE; CYTOKINE RELEASE SYNDROME; EVENT FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMAGNETIC SEPARATION; INTENTION TO TREAT ANALYSIS; KARNOFSKY PERFORMANCE STATUS; LEUKEMIA REMISSION; LIFE EXPECTANCY; LYMPHOCYTE COUNT; MALE; MAXIMUM TOLERATED DOSE; NEUROTOXICITY; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TREATMENT DURATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; IMMUNOLOGY; INFANT; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; REMISSION; TRANSPLANTATION; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIGENS, CD19; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, ANTIGEN, T-CELL; REMISSION INDUCTION; YOUNG ADULT;

EID: 85019806116     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-02-769208.     Document Type: Article

References (19)

1. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16): 1507-1517.
2. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967): 517-528.
3. Turtle CJ, Hanafi LA, Berger C, et al. CD19 CART cells of defined CD41: CD81 composition in adult B cell ALL patients. J Clin Invest. 2016; 126(6): 2123-2138.
4. Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD81 and CD41 CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355): 355ra116.
5. Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303): 303ra139.
6. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177): 177ra38.
7. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224): 224ra25.
8. Singh N, Perazzelli J, Grupp SA, Barrett DM. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci Transl Med. 2016;8(320): 320ra3.
9. Kawalekar OU, O’Connor RS, Fraietta JA, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells [published correction appears in Immunity. 2016;44(3): 712]. Immunity. 2016;44(2): 380-390.
10. Sommermeyer D, Hudecek M, Kosasih PL, et al. Chimeric antigen receptor-modified T cells derived from defined CD81 and CD41 subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30(2): 492-500.
11. Hudecek M, Sommermeyer D, Kosasih PL, et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2015; 3(2): 125-135.
12. Wang X, Chang WC, Wong CW, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood. 2011;118(5): 1255-1263.
13. Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17(10): 1290-1297.
14. Yang S, Ji Y, Gattinoni L, et al. Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunol Immunother. 2013;62(4): 727-736.
15. Gardner R, Wu D, Cherian S, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127(20): 2406-2410.
16. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12): 2709-2720.
17. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121(5): 1822-1826.
18. Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5(12): 1282-1295.
19. Haso W, Lee DW, Shah NN, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121(7): 1165-1174.